Ionis Pharmaceuticals (IONS) News Today

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is trading lower as investors react to a wave of negative headlines centered on its late-stage cardiovascular trial failure. The biggest driver is the announcement that Ionis and AstraZeneca’s Phase 3 CARDIO-TTRansform study for eplontersen/Wainua did not meet its primary endpoint, which raises concerns about the commercial outlook for the program and the broader pipeline.

• Negative Sentiment: Ionis and AstraZeneca disclosed that the Phase 3 CARDIO-TTRansform trial for eplontersen in ATTR-CM failed to hit its main efficacy goal, a major setback for a key partnered drug. Article Title
• Negative Sentiment: Reuters reported that the AstraZeneca-Ionis heart drug also missed its main goal of reducing cardiovascular deaths and recurrent heart problems, reinforcing investor concerns about the program. Article Title
• Negative Sentiment: Several insiders, including an executive vice president and a director, disclosed stock sales under pre-arranged 10b5-1 plans, adding to near-term caution.
• Negative Sentiment: Traders bought an unusually large number of put options, suggesting some market participants are positioning for further downside.
• Neutral Sentiment: Multiple analysts cut price targets on IONS, but most kept Buy/Overweight ratings, indicating valuation confidence even after the setback. Article Title
• Neutral Sentiment: HC Wainwright, Morgan Stanley, Canaccord Genuity, and Needham all lowered targets, with Needham trimming its target to $86 from $105 while maintaining a Buy rating. Article Title
• Neutral Sentiment: Ionis updated FY2026 revenue guidance to $875 million-$900 million, roughly in line with expectations, which does little to offset the clinical disappointment.

In short, IONS is under pressure because the market is repricing the company after a high-profile trial miss, and the negative sentiment is being amplified by analyst target cuts, insider selling disclosures, and bearish options activity.